
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
During our conversation, Reeve pushes an even broader agenda: getting pharmaceutical companies to realize the huge market potential in spinal-cord research for a host of neurological conditions. He implores companies to put their attention, and their investment, into enterprises that are creating breakthroughs in new technologies promising wide therapeutic application.
almost 26 years ago
The Top Ten Marketing Challenges in Neurologyalmost 26 years ago
A Right to Dreamalmost 26 years ago
Woman With a Mission: Pfizer's Lisa Egbuonu-Davis





